...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys
【24h】

The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys

机译：重组嵌合人类副流感病毒1型候选疫苗rHPIV3-1cp45在非洲绿猴中具有减毒，免疫原性和保护性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A recombinant live-attenuated chimeric human parainfluenza virus type I (HPIV1) candidate vaccine was previously generated by replacing the fusion (F) and hemagglutinin-neuraminidase (HN) glycoprotein open reading frames (ORFs) of the HPIV3 candidate vaccine, rHPIV3cp45, with those of wild-type HPIV1. Previously, this recombinant chimeric virus, designated rHPIV3-1 cp45, exhibited a greater level of the temperature sensitivity of replication in vitro and a greater level of attenuation of replication in the respiratory tract of immunized hamsters when compared to its HPIV3cp45 parent virus. In the present study, rHPIV3-1cp45 was evaluated for its level of attenuation and efficacy in African green monkeys (Cercopithecus aethiops), a primate in which both HPIV I and HPIV3 wild-type viruses replicate efficiently. The rHPIV3-1cp45 candidate vaccine was as restricted in replication in the upper and lower respiratory tract as its thoroughly characterized rHPIV3cp45 parent indicating that the attenuating mutations present in the rHPIV3cp45 backbone specified an appropriate level of attenuation of rHPIV3-1 ep45 for primates. The level to which rHPIV3-1 cp45 replicated in the respiratory tract of African green monkeys was also sufficient to induce a strong immune response to HPIV1 and provided protection against challenge with wild-type HPIV1. These results provide a basis for further evaluation of this HPIV1 candidate vaccine in humans.
机译：先前通过用HPIV3候选疫苗rHPIV3cp45替换融合（F）和血凝素神经氨酸酶（HN）糖蛋白开放阅读框（ORF）来产生重组减毒活的I型人类副流感病毒候选疫苗。野生型HPIV1。以前，这种重组嵌合病毒称为rHPIV3-1 cp45，与其HPIV3cp45亲本病毒相比，其在体外复制的温度敏感性更高，在免疫仓鼠的呼吸道中复制的减弱程度更高。在本研究中，评估了rHPIV3-1cp45在非洲绿猴（Cercopithecus aethiops）中的减毒水平和功效，灵长类动物中的HPIV I和HPIV3野生型病毒均能有效复制。 rHPIV3-1cp45候选疫苗由于其彻底表征的rHPIV3cp45亲本在上呼吸道和下呼吸道中的复制受到限制，这表明存在于rHPIV3cp45骨架中的减毒突变为灵长类动物指定了rHPIV3-1 ep45的适当减毒水平。 rHPIV3-1 cp45在非洲绿猴呼吸道中复制的水平也足以诱导对HPIV1的强烈免疫反应，并提供针对野生型HPIV1攻击的保护。这些结果为进一步评估人中这种HPIV1候选疫苗提供了基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号